FDA Approves Blood Test to Predict Coronary Heart Disease Risk
Early detection is the key to surviving and beating many diseases, and a new blood test could help give heart disease patients a head start in preventing serious health events. The U.S. Food and Drug Administration (FDA) recently approved a new blood test that can predict a patient’s risk for developing coronary heart disease.
The test, known as the PLAC Test for Lp-PLA2, is successful in detecting early signs of coronary heart disease risk in both men and women with no history of heart disease. During trial studies, researchers found that the test was particularly successful in predicting coronary heart disease in women.
The PLAC Test measures the amount of the enzyme Lp-PLA2 in the blood. Results of over 225 nanomoles per minute per milliliter in a blood sample mean the patient is at high risk of heart attack or stroke in the future. Due to the varied range of results between genders and ethnicities, the test comes with multiple performance references for the different groups – black women, white women, black men, and white men.
Heart disease is the number one cause of death for both men and women in the United States. It is responsible for one in four female deaths in the U.S. Coronary heart disease is the most common form of heart disease. Many victims of CHD have no prior symptoms or indications that a CHD episode is eminent, and doctors are hoping that this new test will help catch and correct risk factors before a heart attack or stroke occurs.
Coronary heart disease is one of the many types of disabling conditions that may qualify a person for Social Security disability benefits. If you or a loved one suffered a coronary episode and can no longer work and perform substantial gainful activity, you may be eligible for Social Security disability benefits. Disability Help Group helps disabled individuals and their families fight for their rightful benefits. For assistance and support for your claim, call today – 1-(800)-800-3332.